Mounjaro® (Tirzepatide), a dual GIP/GLP-1 receptor agonist, represents a major advancement in Type 2 Diabetes (T2D) care. Approved by the FDA in 2022, it combines glycemic control with weight loss benefits, exceeding results from standard GLP-1 therapies. The SURPASS-4 trial highlighted Tirzepatide’s reduced mortality rate compared to insulin glargine, emphasizing its broader health impact. It’s well-tolerated with manageable side effects, making it a key treatment for complex metabolic needs. Its unique pharmacology could pave the way for future obesity and chronic disease studies.
Gallwitz, B., 2022. Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity. Frontiers in Endocrinology.
Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.
For detailed information about Tirzepatide by Baboon Pharma, consult with your doctor or healthcare professional.
Gallwitz, B., 2022. Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity. Frontiers in Endocrinology.
Gallwitz, B., 2022. Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity. Frontiers in Endocrinology.
Gallwitz, B., 2022. Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity. Frontiers in Endocrinology.
Home
